About Kleo Pharmaceuticals
Kleo Pharmaceuticals is a company based in New Haven (United States) founded in 2015 was acquired by Biohaven Pharmaceutical in January 2021.. Kleo Pharmaceuticals has raised $34.74 million across 4 funding rounds from investors including Biohaven Pharmaceutical, Gates Foundation and PeptiDream. The company has 20 employees as of December 31, 2022. Kleo Pharmaceuticals operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter New Haven, United States
- Employees 20 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kleo Pharmaceuticals Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$34.74 M (USD)
in 4 rounds
-
Latest Funding Round
$5 M (USD), Grant
Jul 08, 2020
-
Investors
Biohaven Pharmaceutical
& 2 more
-
Employee Count
20
as on Dec 31, 2022
-
Acquired by
Biohaven Pharmaceutical
(Jan 08, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kleo Pharmaceuticals
Kleo Pharmaceuticals has successfully raised a total of $34.74M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $5.0M
- First Round First Round
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Grant - Kleo Pharmaceuticals | Valuation |
investors |
|
| Nov, 2018 | Amount | Series B - Kleo Pharmaceuticals | Valuation | PeptiDream | |
| May, 2018 | Amount | Series A - Kleo Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kleo Pharmaceuticals
Kleo Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Biohaven Pharmaceutical, Gates Foundation and PeptiDream. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for neurological and neuropsychiatric diseases are developed.
|
Founded Year | Domain | Location | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location | |
|
Peptide-based drugs are developed for diverse medical indications.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kleo Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kleo Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kleo Pharmaceuticals Comparisons
Competitors of Kleo Pharmaceuticals
Kleo Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kleo Pharmaceuticals
Frequently Asked Questions about Kleo Pharmaceuticals
When was Kleo Pharmaceuticals founded?
Kleo Pharmaceuticals was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Kleo Pharmaceuticals located?
Kleo Pharmaceuticals is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Is Kleo Pharmaceuticals a funded company?
Kleo Pharmaceuticals is a funded company, having raised a total of $34.74M across 4 funding rounds to date. The company's 1st funding round was a Series A of $13.53M, raised on Sep 01, 2016.
How many employees does Kleo Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Kleo Pharmaceuticals is 20.
What does Kleo Pharmaceuticals do?
Kleo Pharmaceuticals is developing a new class of immunotherapies utilizing small molecules to activate an individuals own immune system to fight against cancers and infectious diseases. It is developing two types of small molecules Antibody-Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). ARMs are bifunctional or two-headed chemical structures designed such that one head interacts with disease-relevant molecular targets (such as cancers), while the other head interacts directly with antibodies already present in a persons bloodstream. SyAMs are novel synthetic molecules that possess both the targeting and effector cell-activating functions of antibodies.
Who are the top competitors of Kleo Pharmaceuticals?
Kleo Pharmaceuticals's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Who are Kleo Pharmaceuticals's investors?
Kleo Pharmaceuticals has 3 investors. Key investors include Biohaven Pharmaceutical, Gates Foundation, and PeptiDream.